Pfizer’s quit-smoking drug not linked to depression or heart risks

By Kate Kelland LONDON (Reuters) – Pfizer's stop-smoking drug Chantix does not raise risks of heart attack or depression, contrary to previous reports, and should be recommended to more smokers wanting to quit, scientists said on Monday. In a study tracking 150,000 smokers in England for 6 months, researchers found that patients who took Chantix, known generically as varenicline and marketed as Champix in Europe, were no more likely to suffer a heart attack than those using nicotine replacement therapy or another quit-smoking drug.

Original post: 
Pfizer’s quit-smoking drug not linked to depression or heart risks